Navigation Links
NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
Date:8/19/2008

2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Company's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that the patent litigation described in this press release will result in significant expenses for the Company; the risk that this litigation could result in damages awards against the Company, including the possibility of treble damages if the Company is ultimately determined to have infringed; the risk that this litigation will divert the attention of management; the risk that the Company's defenses or counterclaims to this litigation may prove ineffective; the uncertain process of seeking regulatory approval
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
2. NuVasive Acquires First Stem Cell Bone Graft Substitute
3. NuVasive Reports First Quarter 2008 Financial Results
4. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
5. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Present at BIOCOM Investor Conference 2007
8. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
9. NuVasive Licenses Its Insert and Rotate Technology
10. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
11. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... (PRWEB) May 05, 2015 With the FCPX ... can quickly and easily add washed color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 90 washed CUBE LUT files. , This ... Monochromatic can give any footage a washed look. , ...
(Date:5/5/2015)... 2015 Private equity consultant and international ... announced that its dental stem cell biobank project, ... again--in April, 2015 –and posted yet another exciting record. ... volume and represents a significant 54% increase over last ... biobank is conducted via the Store-A-Tooth brand. The company ...
(Date:5/5/2015)... Beverly Hills Cosmetic Dentist, Arthur Glosman released a luxury ... sold at the offices of Arthur Glosman DDS, 450 N ... an online store . “I wanted to be one ... care and beauty with a luxurious collection of products designed ... , Dr. Glosman’s Advanced Dental Health + Beauty™ products ...
(Date:5/5/2015)... NCPDP announced today that AmerisourceBergen ... a three-year commitment of strategic support for NCPDP, and ... “AmerisourceBergen has supported our multi-stakeholder forum over 3 decades,” ... is a wonderful continuation and expansion of its commitment ... back to our very first Board of Trustees in ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), ... billion peripheral nerve repair market, reported record revenue of ... 2015 compared to $3.14 million in the year-ago first ... proprietary portfolio of nerve repair products - Avance® ... – and our solid sales execution delivered another record ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... to Nutrition experts, some new ways of getting the ... that omega-6 fatty acids are associated with chronic diseases, ... regular daily diet naturally// includes some of each. ... your omega-3s from fish like sardines, salmon and tuna. ...
... spend more for health care and medications than smokers, ... health hazards. While tobacco is still the nation's principal ... obesity was running a close second. ,For ... Corp. economist Roland Sturm used data from two national ...
... human diet mean people today are more at risk of ... the University of Newcastle believe that changes to the way ... anti-cancer agents. ,The researchers are working on a ... stomach cancer. They are carrying out two trials on people ...
... in hospital who smoke and have a history of ... surveyed almost 400 patients// to find if there was ... classified them into four groups:current tobacco use only, history ... ,The patients with both current tobacco use and past ...
... According to researchers reducing weight and increasing exercise cut ... have elevated blood sugar are known to be at ... serious even life-threatening complications, it would be very useful ... individuals avoid the disease. ,Researchers for the ...
... longtime sufferers. New research shows that a combination of ... the severity and frequency of chronic tension headches, which ... people with mild to moderate head pain that occurs ... six months. Although antidepressants require a prescription, they may ...
Cached Medicine News:
(Date:5/5/2015)...  Adeptus Health Inc. (NYSE: ADPT ) (the ... the previously announced offering of 2,100,000 shares of its ... to be sold by the Company, and 750,329 shares ... Partners (the "Selling Stockholder"), at a price to the ... and the Selling Stockholder have granted the underwriters an ...
(Date:5/5/2015)... BOSTON , May 5, 2015   InspireMD, Inc. ... in embolic protection systems, announced today that it will release ... 31, 2015 on Monday, May 11 th before the ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Symphony family of Pacemakers, Ela presents the ... lighter than a passport, will take your ... technologies, and delivering powerful monitoring. ELA ... dual-chamber and atrial tracking modes in patients ...
Medicine Products: